@article {Lazzerini2021.03.17.21253610, author = {Marzia Lazzerini and Idanna Sforzi and Sandra Trapani and Paolo Biban and Davide Silvagni and Ilaria Mariani and Giovanna Villa and Jessica Tibaldi and Luca Bertacca and Enrico Felici and Giuseppina Perricone and Roberta Parrino and Claudia Gio{\`e} and Sara Lega and Mariasole Conte and Federico Marchetti and Annamaria Magista and Paola Berlese and Stefano Martelossi and Francesca Vaienti and Enrico Valletta and Margherita Mauro and Roberto Dall{\textquoteright}Amico and Silvia Fasoli and Antonio Gatto and Antonio Chiaretti and Danica Dragovic and Paola Pascolo and Chiara Pilotto and Ilaria Liguoro and Elisabetta Miorin and Francesca Saretta and Gianluca Trobia and Antonella Di Stefano and Azzurra Orlandi and Fabio Cardinale and Riccardo Lubrano and Alessia Testa and Marco Binotti and Valentina Moressa and Egidio Barbi and Benedetta Armocida}, editor = {,}, title = {Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers}, elocation-id = {2021.03.17.21253610}, year = {2021}, doi = {10.1101/2021.03.17.21253610}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background No study has described factors associated with COVID-19 diagnosis in children.Aim Describe characteristics and risk factors for COVID-19 diagnosis in children tested in 20 pediatric centers across Italy.Methods Cases aged 0-18 years tested for SARS-CoV-2 between February 23 and May 24 2020 were included. Our primary analysis focused on children tested because of COVID-19 suggestive symptoms.Results Among 2494 children tested for SARS-CoV-2, 2148 (86.1\%) had symptoms suggestive of COVID-19. Clinical presentation of SARS-CoV-2 included - beside fever (82.4\%) and respiratory signs or symptoms (60.4\%) {\textendash} also gastrointestinal (18.2\%), neurological (18.9\%), cutaneous (3.8\%) and other flu-like presentations (17.8\%). In multivariate analysis, factors significantly associated with SARS-CoV-2 were: exposure history (adjusted OR 39.83 95\%CI 17.52-90.55 p\<0.0001), cardiac disease (adjusted OR 3.10 95\%CI 1.19-5.02 p\<0.0001), fever (adjusted OR 3.05 \% 95\% CI 1.67-5.58 p=0.0003), and anosmia/ageusia (OR 4.08 95\%CI 1.69 -9.84 p=0.002). Among 190 (7.6\%) children diagnosed with SARS-CoV-2, only four (2.1\%) required respiratory support and two (1.1\%) were admitted in ICU, while 100\% recovered.Conclusion Recommendations for SARS-CoV-2 testing in children should be updated based on the evidence of broader clinical features. Exposure history, fever, and anosmia/ageusia are strong risk factors for COVID-19 in children, while other symptoms don{\textquoteright}t seem helping discriminating in between the SARS-CoV-2 positive and the negative cases. This study confirm that COVID-19 is a mild disease in the general population of children in Italy. Further studies are needed to understand the risk, clinical spectrum and outcomes of COVID-19 in children with specific preexisting conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (reference number 01/2020 25.03.2020).Given the purely descriptive and retrospective nature of the study, informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.}, URL = {https://www.medrxiv.org/content/early/2021/03/17/2021.03.17.21253610}, eprint = {https://www.medrxiv.org/content/early/2021/03/17/2021.03.17.21253610.full.pdf}, journal = {medRxiv} }